Regeneron confirmed it has discontinued development of bbT369, a CAR‑T candidate acquired from 2seventy bio, and will not advance the asset into Phase II. The firm described the decision as a "strategic business decision" after reviewing early data and portfolio priorities following its January acquisition of 2seventy’s pipeline. bbT369 targeted relapsed/refractory B‑cell non‑Hodgkin’s lymphoma and had been slated for further testing. Regeneron said shelving the program will not alter its broader cell‑therapy strategy, but its public pipeline lists only one other cell therapy currently in Phase I, underscoring limited near‑term capacity in that modality. The move is part of a broader retrenchment across cell therapy: several large companies have recently exited or reduced investment in the space, citing commercial and technical headwinds. Regeneron will maintain other acquired assets but will reallocate resources accordingly.